News articles about Mediwound (NASDAQ:MDWD) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mediwound earned a news impact score of 0.09 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.7450730983624 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Mediwound (MDWD) opened at $4.60 on Friday. The company has a market cap of $124.42, a P/E ratio of -4.69 and a beta of -0.01. Mediwound has a 52 week low of $4.15 and a 52 week high of $8.25.
Several research firms have recently commented on MDWD. Oppenheimer restated a “buy” rating and issued a $10.00 price target on shares of Mediwound in a report on Monday, September 18th. Jefferies Group reiterated a “buy” rating and set a $10.00 price objective on shares of Mediwound in a research note on Thursday, September 28th. ValuEngine lowered shares of Mediwound from a “sell” rating to a “strong sell” rating in a research note on Friday, September 22nd. Zacks Investment Research upgraded shares of Mediwound from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research note on Wednesday, October 4th. Finally, Cowen started coverage on shares of Mediwound in a research note on Thursday, September 28th. They set an “outperform” rating and a $9.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $9.13.
TRADEMARK VIOLATION WARNING: “Mediwound (MDWD) Earns Daily News Impact Score of 0.09” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/14/mediwound-mdwd-earns-daily-news-impact-score-of-0-09.html.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.